Biotechnology Tissue Engineering Law In Russia.

Introduction

Biotechnology tissue engineering is an important branch of regenerative medicine that combines living cells, biomaterials, biological scaffolds and advanced engineering techniques to repair, replace or regenerate damaged human tissues.

In Russia, tissue engineering is regulated through a combination of biomedical cell-product legislation, healthcare legislation, medical-device regulation, transplantation rules, clinical research requirements and civil liability principles.

The principal legislation is Federal Law No. 180-FZ of 23 June 2016, On Biomedical Cell Products (О биомедицинских клеточных продуктах).

This legislation establishes a special regulatory framework for developing, testing, registering, manufacturing and applying biomedical cell products. However, not every tissue-engineered product automatically falls within this law. Its legal classification depends on whether it contains living cell lines, how it is manufactured and its intended medical purpose.

cis-legislation.com+2

 

1. Meaning and Scope of Tissue Engineering

Tissue engineering involves the development of biological substitutes that restore, maintain or improve the functioning of damaged tissues.

Examples include:

Engineered skin for burn treatment.

Cartilage regeneration products.

Bone tissue substitutes containing living cells.

Artificial corneal tissue.

Regenerative vascular structures.

Laboratory-developed biological tissues.

Cell-based wound-healing materials.

Tissue-engineered products used in reconstructive surgery.

Three principal components are involved:

Cells: Stem cells, differentiated cells or other cellular materials.

Scaffolds: Structures that support cell growth and tissue formation.

Signalling factors: Biological substances that regulate cellular growth and differentiation.

The legal system must address the safety of each component and the safety of the final engineered product.

2. Constitutional and Legislative Foundation

The Russian Constitution provides the fundamental legal framework for protecting human life, health, dignity and personal rights.

Important constitutional provisions include:

Article 20 – Right to life.

Article 21 – Protection of human dignity.

Article 41 – Right to health protection and medical assistance.

Article 35 – Protection of property rights, relevant to commercial biotechnology and intellectual property.

These constitutional guarantees influence the interpretation of legislation governing tissue engineering, human biological materials and experimental medical treatment.

The principal statutory framework includes:

LegislationLegal significance
Federal Law No. 180-FZ (2016)Biomedical cell products
Federal Law No. 323-FZ (2011)Fundamental healthcare and patient rights
Federal Law No. 61-FZ (2010)Medicinal products
Federal Law No. 99-FZ (2011)Licensing of activities
Federal Law No. 152-FZ (2006)Personal data protection
Federal Law No. 38-FZ (1995)Advertising restrictions, including medical advertising

An important distinction is that Law No. 180-FZ excludes ordinary organ and human-tissue donation for transplantation, conventional medicines, medical devices and certain scientific or educational activities from its scope. Therefore, tissue engineering must be classified carefully before selecting a regulatory route.

cis-legislation.com+2

 

3. Federal Law No. 180-FZ: Biomedical Cell Products

Principal legislation

Federal Law No. 180-FZ was adopted on 23 June 2016 and established a specific regulatory system for biomedical cell products.

It regulates:

Development of biomedical cell products.

Preclinical research.

Clinical investigations.

Biological-material donation.

Product examination.

State registration.

Manufacturing.

Quality control.

Distribution and application.

Storage and transportation.

Safety monitoring.

Legal responsibility and compensation.

The law is particularly important where tissue-engineered products contain living cell lines combined with auxiliary substances, registered medicinal products or medical devices.

Important statutory provisions

Article 1 – Scope of regulation

Defines the activities and products covered by the legislation.

Article 2 – Basic definitions

Provides the terminology necessary to determine whether a product qualifies as a biomedical cell product.

Article 8 – State registration

Establishes registration requirements before ordinary commercial circulation and medical application.

Article 9 – Registration documentation

Deals with the application and registration dossier.

Article 35 – Manufacturing and distribution

Establishes requirements concerning manufacturing regulations and the circulation of biomedical cell products.

Articles 47–48 – Responsibility and compensation

These provisions are relevant when examining legal responsibility and compensation for harm associated with biomedical cell products.

The precise application of each provision depends on the product's classification and the applicable exceptions.

Consultant Plus+3

 

4. Legal Classification of Tissue-Engineered Products

Product classification is one of the most important legal questions in Russian tissue engineering.

A product may fall into different regulatory categories.

Product categoryPotential regulatory framework
Living-cell-based engineered tissueLaw No. 180-FZ
Acellular biological scaffoldMedical-device or other applicable framework
Medicinal growth-factor preparationLaw No. 61-FZ
Donated human tissue for transplantationTransplantation legislation
Laboratory tissue for scientific researchResearch and applicable biosafety rules
Combined cell-device productClassification under the relevant overlapping regimes

For example, a laboratory-developed skin substitute containing living human cells may qualify as a biomedical cell product.

By contrast, a synthetic scaffold without living cellular material may be regulated as a medical device.

This distinction is essential because the approval, testing and manufacturing obligations can differ considerably.

5. State Registration and Regulatory Approval

Russia requires regulatory approval before ordinary circulation of biomedical cell products.

Under Article 8 of Law No. 180-FZ, registration involves several forms of examination.

These include:

Quality examination.

Examination of clinical-investigation documentation.

Evaluation of product effectiveness.

Assessment of the relationship between expected benefits and potential risks.

Ethical examination of the proposed clinical investigation.

Clinical investigations.

The statutory registration period is generally 150 working days, potentially extending to 250 working days where repeat examination is required.

The competent federal authority is the Russian Ministry of Health.

The registration process is designed to prevent unsafe biological products from entering medical practice without adequate evidence of quality, safety and effectiveness.

Consultant Plus+1

 

6. Clinical Trials and Human-Subject Protection

Tissue-engineered products frequently require clinical investigation before approval.

Clinical research must address:

Scientific validity.

Patient selection.

Informed consent.

Ethical approval.

Clinical monitoring.

Adverse-event reporting.

Researcher qualifications.

Protection of vulnerable participants.

Documentation of clinical outcomes.

Federal Law No. 323-FZ provides the broader foundation for patient rights and medical intervention.

Article 20 is particularly important because it establishes the general framework for informed voluntary consent to medical intervention.

In tissue engineering, informed consent should explain:

The experimental nature of the treatment.

Potential benefits and risks.

Alternative treatments.

Possible complications.

The use of biological materials.

The possibility of treatment failure.

The handling of personal and genetic information.

Legal issue: A patient cannot be treated as having consented to an experimental tissue-engineering procedure merely because the patient signed a general hospital admission document.

The nature and risks of the proposed intervention must be adequately communicated.

7. Stem Cells and Biological-Material Donation

Tissue engineering frequently depends on human stem cells and other biological materials.

The source of the cells creates important legal questions.

Three principal categories are relevant:

A. Autologous cells

These are obtained from the same individual who will receive the engineered tissue.

For example, skin cells may be collected from a patient, expanded in a laboratory and used to develop a tissue substitute for that patient.

B. Allogeneic cells

These are obtained from another individual.

This raises additional questions involving donor consent, traceability, biological compatibility and potential immune reactions.

C. Combined cellular products

These involve combinations of different cellular materials or other regulated components.

The regulatory framework must address:

Donor identification.

Consent to biological-material donation.

Collection procedures.

Storage conditions.

Cell-line identification.

Contamination prevention.

Traceability.

Confidentiality.

Permitted use of donated material.

An important legal distinction exists between biological material used to manufacture a biomedical cell product and human organs or tissues donated for conventional transplantation. The two activities are not automatically governed by the same legislation.

8. Manufacturing Standards and Quality Control

Tissue-engineered products require strict manufacturing controls because biological materials can change during collection, processing, storage and transportation.

Article 35 of Law No. 180-FZ requires manufacturing to follow an approved manufacturing regulation.

Government Resolution No. 1184 of 3 October 2018 establishes the licensing framework for manufacturing biomedical cell products.

The licensing authority is Roszdravnadzor, the Federal Service for Surveillance in Healthcare.

Important manufacturing requirements include:

Appropriate production facilities.

Qualified personnel.

Suitable laboratory equipment.

Documented manufacturing procedures.

Quality-control systems.

Prevention of contamination.

Proper storage and transportation.

Product traceability.

Manufacturers must establish procedures for controlling the identity, composition, purity and biological characteristics of the product.

For example, a cartilage-engineering manufacturer should establish controls to demonstrate that the cells used in production are correctly identified, adequately characterised and suitable for the intended clinical application.

Consultant Plus+2

9. Medical Device Regulation and Tissue Engineering

Not every tissue-engineering technology is a biomedical cell product.

Acellular scaffolds, artificial membranes, specialised implants and other tissue-supporting technologies may fall under medical-device legislation.

Federal Law No. 323-FZ and the applicable medical-device regulatory framework are relevant.

Roszdravnadzor supervises medical-device registration and circulation.

Under the Russian medical-device definition, a device intended to replace or modify anatomical structures or physiological functions may qualify as a medical device where its principal action is not achieved through pharmacological, immunological, genetic or metabolic means.

This creates an important regulatory distinction:

Living-cell-based tissue products may fall under Law No. 180-FZ.

Non-cellular scaffolds may fall under medical-device regulation.

Products combining cells and devices may require careful assessment of the applicable regimes.

The Eurasian Economic Union's medical-device framework may also become relevant to products seeking circulation in multiple EAEU member states.

roszdravnadzor.gov.ru+1

 

10. Individualised Tissue Engineering and Hospital Manufacturing

Individualised tissue engineering is particularly important in regenerative medicine.

For example, a hospital may want to manufacture a cell-based tissue product specifically for one patient rather than manufacture it for general commercial distribution.

The 2023 amendments to Law No. 180-FZ introduced a specific framework for biomedical cell products intended for individual medical use.

Two important implementing instruments were adopted on 28 March 2024:

Government Resolution No. 384 – Rules concerning individual-use human cell-based products manufactured directly at the medical organisation where they are used.

Government Resolution No. 385 – Rules for granting, confirming and revoking authorisation for manufacturing and using such products.

These arrangements create a special regulatory pathway, rather than simply treating every individually manufactured product as an ordinary commercial product.

However, individual manufacture does not mean that safety, quality, professional competence and patient protection requirements disappear.

The State Scientific Centre for Expert Evaluation of Medicinal Products also provides expert evaluation services for these products.

regmed.ru+1

 

11. Patient Rights and Medical Negligence

Tissue engineering creates potential liability when a patient suffers harm because of defective products, inadequate medical supervision or negligent treatment.

Federal Law No. 323-FZ provides the broader patient-protection framework.

Relevant legal questions include:

Was the patient properly informed?

Was the product legally authorised?

Was the procedure performed by qualified professionals?

Were accepted medical standards followed?

Was the biological material correctly identified?

Was the patient monitored after treatment?

Was the complication reported and investigated?

Potentially responsible parties include:

Tissue-engineering manufacturers.

Medical organisations.

Clinical investigators.

Laboratory operators.

Healthcare professionals.

Distributors and other responsible participants in the supply chain.

Russian civil law may also become relevant.

Articles 1064 and 1068 of the Civil Code of the Russian Federation provide important foundations for compensation for harm and employer responsibility for harm caused by employees.

Article 1095 is relevant to harm caused by defects in goods, work or services, subject to its statutory conditions.

Example: If a manufacturer releases a contaminated cellular tissue product and a patient develops a serious infection, questions may arise concerning manufacturing negligence, product defects, regulatory compliance and compensation.

The precise defendant and legal basis depend on the facts and the relationship between the parties.

12. Intellectual Property Protection

Tissue engineering also raises significant intellectual-property questions.

Commercially valuable innovations may include:

Novel scaffold designs.

Cell-culture technologies.

Bioprinting methods.

Tissue-regeneration processes.

Manufacturing equipment.

Laboratory techniques.

Biomaterial compositions.

Federal Law No. 2300-I on Consumer Protection may also be relevant to the commercial supply of healthcare-related products and services, depending on the circumstances.

Patent protection is primarily governed by Part IV of the Russian Civil Code.

However, the human body and its natural biological processes must be distinguished from patentable technical inventions.

A laboratory-developed manufacturing method may be eligible for protection if it satisfies the relevant patentability requirements. That does not automatically make the biological material itself patentable.

A further issue is ownership of research results created through cooperation between universities, hospitals and private biotechnology companies.

Contracts should clearly address:

Ownership of inventions.

Patent applications.

Research publications.

Confidential information.

Licensing rights.

Commercialisation revenue.

13. Data Protection and Genetic Information

Tissue engineering may involve highly sensitive personal information.

Examples include:

Genetic profiles.

Cellular characteristics.

Donor information.

Medical histories.

Biopsy records.

Laboratory test results.

Treatment outcomes.

Federal Law No. 152-FZ on Personal Data Protection is important in this context.

Article 10 provides special protection for specified categories of sensitive personal data, including information concerning health.

The use of genetic and cellular information therefore requires careful attention to lawful processing, consent where required, confidentiality and appropriate security measures.

A tissue-engineering organisation must also distinguish between:

Biological material itself.

Personal data connected with that material.

Research information derived from the material.

Commercially valuable laboratory results.

These are legally distinct interests.

14. Ethical and Biosecurity Responsibilities

Tissue engineering can involve stem-cell manipulation, genetic modification and advanced biological manufacturing.

Consequently, ethical and biosecurity safeguards are important.

Major issues include:

Human dignity: Biological materials must not be exploited in ways inconsistent with applicable human-rights and healthcare protections.

Research ethics: Clinical investigations must undergo appropriate ethical assessment.

Genetic modification: Additional regulatory questions arise where engineered tissues contain genetically modified cells.

Animal-derived materials: Biological scaffolds derived from animals may require additional veterinary, sanitary and biosecurity controls.

Biological contamination: Laboratories must prevent the introduction and transmission of infectious agents.

Commercial exploitation: Organisations must comply with applicable restrictions concerning donation, commercial activity and the use of human biological materials.

The legal challenge is to balance scientific innovation with patient safety and ethical responsibility.

15. Important Russian Case Laws

Russian judicial decisions specifically concerning tissue engineering and biomedical cell products remain relatively limited. There is an important distinction between cases dealing directly with Law No. 180-FZ and earlier cases involving cellular medical technologies.

The following decisions are relevant to understanding the development of Russian biotechnology regulation.

Case 1. Institute of Human Stem Cells v. Roszdravnadzor

Important related precedent

Court: Supreme Court of the Russian Federation

Date: 13 June 2017

Case number: 305-КГ17-6103

Underlying case: А40-58903/2016

Facts:

The Public Joint-Stock Company Institute of Human Stem Cells challenged an enforcement order issued by Roszdravnadzor.

The institute possessed a medical licence covering high-technology medical assistance involving cellular technologies.

Roszdravnadzor conducted an inspection and identified problems concerning compliance of the institute's medical licence with applicable licensing requirements.

The institute challenged the enforcement order.

Legal issue:

Whether the existing medical licence complied with the applicable Russian licensing requirements.

Judicial outcome:

The Moscow Arbitration Court rejected the institute's claim.

The Ninth Arbitration Court of Appeal reversed that decision.

The Moscow District Arbitration Court reinstated the first-instance decision on 21 February 2017.

On 13 June 2017, the Supreme Court refused to transfer the institute's cassation complaint for consideration by its Judicial Collegium.

Legal significance:

The case illustrates that possessing a licence for medical activity involving cellular technologies does not automatically establish compliance with all applicable licensing requirements.

It is particularly relevant to organisations developing cellular therapies and regenerative medicine services.

Important limitation: This dispute predates the effective operation of Law No. 180-FZ. It should therefore be treated as a related cellular-technology licensing precedent, not as a judicial interpretation of the later tissue-engineering registration framework.

ГАРАНТ+1

 

Case 2. European Court of Human Rights – S.H. and Others v. Austria

Court: European Court of Human Rights

Date: 3 November 2011

Application No.: 57813/00

Facts:

The case concerned restrictions on certain assisted reproductive technologies involving donated reproductive cells.

Legal issue:

Whether restrictions on reproductive technologies violated the applicants' rights under Article 8 of the European Convention on Human Rights.

Legal significance:

The judgment provides useful comparative principles concerning reproductive biotechnology, scientific developments, individual autonomy and the state's regulatory discretion.

However, it is not a Russian tissue-engineering judgment and should not be presented as binding Russian domestic precedent.

Case 3. European Court of Human Rights – Evans v. United Kingdom

Court: European Court of Human Rights, Grand Chamber

Date: 10 April 2007

Application No.: 6339/05

Facts:

The dispute concerned the continued storage and use of embryos created through assisted reproductive technology.

Legal significance:

The Court considered reproductive autonomy, consent and the competing rights of individuals involved in the use of biological material.

For tissue engineering, the decision provides comparative guidance on the importance of informed consent and the legal status of human biological materials.

Again, it is not a direct Russian tissue-engineering precedent.

Case 4. International and Russian transplantation jurisprudence

Russian legal scholarship also examines judicial and regulatory questions concerning the removal, storage and transplantation of human organs and tissues.

A relevant scholarly discussion is:

V. V. Momotov, Bioethics in the Context of Legislation and Law Enforcement (Organ and Tissue Transplantation), Russian Justice, No. 12 (2019).

It discusses donor consent, protection against involuntary removal of biological materials and the ethical dimensions of transplantation.

These principles are relevant when determining whether an activity is conventional tissue transplantation or the manufacture and application of a biomedical cell product.

rgup.ru+1

 

Case-law conclusion: The identified Russian judicial record does not establish a substantial body of reported judgments specifically interpreting tissue-engineering products under Law No. 180-FZ. The Institute of Human Stem Cells case is the clearest directly relevant domestic licensing dispute identified here. The other judgments are comparative authorities, not Russian binding precedents.

16. Regulatory Authorities Responsible for Tissue Engineering

Several Russian institutions participate in regulating tissue engineering.

AuthorityMain responsibility
Ministry of HealthBiomedical cell-product registration and healthcare policy
RoszdravnadzorHealthcare supervision and manufacturing licensing
State Scientific Centre for Expert Evaluation of Medicinal ProductsScientific and expert evaluation
Ethical review bodiesEthical assessment of clinical investigations
RospotrebnadzorSanitary and epidemiological supervision
Federal Service for Intellectual Property (Rospatent)Patent and intellectual-property administration

Their respective responsibilities depend on the nature of the product and the activity being performed.

17. Major Legal Challenges in Russian Tissue Engineering

Several unresolved or developing regulatory issues deserve particular attention.

1. Classification uncertainty

Determining whether a product is a cell product, medical device, medicinal product or transplantable tissue can be difficult.

2. Stem-cell safety

Cellular abnormalities, immune reactions and unexpected tissue growth create important safety concerns.

3. Individualised manufacturing

Personalised tissue products require flexible regulation without weakening quality and safety standards.

4. Cross-border biological materials

International movement of human cells, tissue samples and biological products creates customs, donor-consent, documentation and biosafety questions.

5. Intellectual-property disputes

Conflicts may arise between researchers, hospitals, universities and commercial manufacturers.

6. Product liability

It may be difficult to determine whether responsibility lies with the cell supplier, scaffold manufacturer, laboratory or treating hospital.

7. Long-term monitoring

Some regenerative products may have effects that cannot be adequately assessed through short-term clinical observation.

8. Genetic engineering

The use of genetically modified cells creates additional regulatory and ethical questions.

18. Practical Example: Tissue-Engineered Skin for Burn Patients

Consider a Russian biotechnology company developing an engineered skin product using living human cells and a biodegradable scaffold.

Inside the Lab that Grows Human Skin to Test Your Cosmetics | WIRED

 

 

3D-bioprinted human skin model expands options for preclinical research - Mayo Clinic News Network

 

 

Advances in the Research of Bioinks Based on Natural Collagen, Polysaccharide and Their Derivatives for Skin 3D Bioprinting

 

9

 

The legal process may involve the following stages:

StageLegal requirement
Cell collectionLawful biological-material donation
Cell processingApplicable manufacturing requirements
Scaffold developmentMedical-device classification assessment
Preclinical testingSafety and effectiveness evaluation
Clinical investigationAuthorisation and ethical assessment
RegistrationApplicable product-registration procedure
ManufacturingAppropriate production licensing
Hospital applicationPatient consent and clinical compliance
Follow-upSafety monitoring and adverse-event management

If the product qualifies as a biomedical cell product, Law No. 180-FZ becomes central to its regulatory pathway.

If the product is an acellular scaffold, the applicable medical-device framework may instead govern its registration.

If a patient develops an infection because of contaminated cells, the company, medical organisation and other responsible participants may face different forms of civil or regulatory liability.

19. Important Legal Provisions for Academic Research

Legal sourceRelevant subject
Russian Constitution, Articles 20, 21 and 41Life, dignity and health
Law No. 180-FZ, Article 1Scope of biomedical cell-product legislation
Law No. 180-FZ, Article 8State registration
Law No. 180-FZ, Article 9Registration dossier
Law No. 180-FZ, Article 35Manufacturing and distribution
Law No. 323-FZ, Article 20Informed consent
Law No. 152-FZPersonal-data protection
Law No. 99-FZLicensing
Government Resolution No. 1184 (2018)Manufacturing licensing
Government Resolutions Nos. 384 and 385 (2024)Individual-use cell products
Russian Civil Code, Article 1064Compensation for harm
Russian Civil Code, Article 1068Employer liability

20. Conclusion

Biotechnology tissue engineering in Russia operates within a developing legal framework that combines biomedical cell-product regulation, medical-device legislation, transplantation law, clinical research requirements, patient protection and civil liability.

Federal Law No. 180-FZ of 23 June 2016 is the central legislation for tissue-engineered products that qualify as biomedical cell products.

Its importance lies in establishing requirements for product development, biological-material donation, clinical investigation, registration, manufacturing, quality control and safety.

The amendments introduced in 2023 and the implementing regulations adopted in 2024 are particularly significant because they provide a specific regulatory pathway for certain individually manufactured cell products.

Nevertheless, legal challenges remain concerning product classification, stem-cell safety, personalised manufacturing, biological-material ownership, genetic information, intellectual property and long-term patient protection.

The central legal principle is that scientific innovation in tissue engineering must operate within a framework of patient safety, informed consent, scientific evidence, regulatory accountability and compensation for legally recognised harm.

References and Further Reading

Federal Law No. 180-FZ – On Biomedical Cell Products.

Article 8 – State Registration of Biomedical Cell Products.

Roszdravnadzor – Biomedical Cell Products.

Evaluation of Human Cell-Based Products for Individual Use.

Government Resolution No. 1184 – Manufacturing Licensing.

Almost 40 Years of Tissue Engineering in Russia: Where Are We Now?.

Supreme Court – Case No. 305-КГ17-6103.

Bioethics in the Context of Legislation and Law Enforcement (2019).

Academic note: This explanation is intended for legal and academic research. For litigation, investment or regulatory submissions, the latest consolidated Russian-language legislation and the full court judgments should be checked. The analysis distinguishes binding Russian legislation from comparative international case law.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT